title: Activation of VTA GABA neurons disrupts reward consumption.
abstract: The activity of ventral tegmental area (VTA) dopamine (DA) neurons promotes behavioral responses to rewards and environmental stimuli that predict them. VTA GABA inputs synapse directly onto DA neurons and may regulate DA neuronal activity to alter reward-related behaviors; however, the functional consequences of selective activation of VTA GABA neurons remains unknown. Here, we show that in vivo optogenetic activation of VTA GABA neurons disrupts reward consummatory behavior but not conditioned anticipatory behavior in response to reward-predictive cues. In addition, direct activation of VTA GABA projections to the nucleus accumbens (NAc) resulted in detectable GABA release but did not alter reward consumption. Furthermore, optogenetic stimulation of VTA GABA neurons directly suppressed the activity and excitability of neighboring DA neurons as well as the release of DA in the NAc, suggesting that the dynamic interplay between VTA DA and GABA neurons can control the initiation and termination of reward-related behaviors.
authors.affiliation: Departments of Psychiatry & Cellular and Molecular Physiology, UNC Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
authors.forename: Ruud
authors.initials: R
authors.lastname: van Zessen
authors.forename: Jana L
authors.initials: JL
authors.lastname: Phillips
authors.forename: Evgeny A
authors.initials: EA
authors.lastname: Budygin
authors.forename: Garret D
authors.initials: GD
authors.lastname: Stuber
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics; D001522:Behavior, Animal; D001703:Biophysics; D000075402:Channelrhodopsins; D003463:Cues; D004298:Dopamine / Q000378:metabolism; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000502:physiology*; D004558:Electric Stimulation; D005106:Exploratory Behavior / Q000187:drug effects; D005518:Food Preferences / Q000187:drug effects / Q000502:physiology*; D018756:GABA Antagonists / Q000494:pharmacology; D059330:GABAergic Neurons / Q000187:drug effects / Q000502:physiology*; D066298:In Vitro Techniques; D053444:Inhibitory Postsynaptic Potentials / Q000235:genetics / Q000502:physiology; D008164:Luminescent Proteins / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009434:Neural Pathways / Q000502:physiology; D055095:Optics and Photonics; D018408:Patch-Clamp Techniques; D011724:Pyridazines / Q000494:pharmacology; D012201:Reward; D013378:Substantia Nigra / Q000378:metabolism; D013395:Sucrose / Q000008:administration & dosage; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D017557:Ventral Tegmental Area / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D050495:Vesicular Inhibitory Amino Acid Transport Proteins / Q000235:genetics / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D001426:Bacterial Proteins; D000075402:Channelrhodopsins; D018756:GABA Antagonists; D008164:Luminescent Proteins; D011724:Pyridazines; D050495:Vesicular Inhibitory Amino Acid Transport Proteins; C492244:Viaat protein, mouse; C054562:yellow fluorescent protein, Bacteria; D005680:gamma-Aminobutyric Acid; D013395:Sucrose; C049853:gabazine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine